Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01436305
Recruitment Status : Terminated (Secondary to safety concerns plus change in Campath® (alemtuzumab) availability.)
First Posted : September 19, 2011
Results First Posted : August 30, 2017
Last Update Posted : September 27, 2017
Sponsor:
Collaborator:
Clinical Trials in Organ Transplantation
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)

Tracking Information
First Submitted Date  ICMJE September 13, 2011
First Posted Date  ICMJE September 19, 2011
Results First Submitted Date  ICMJE November 10, 2016
Results First Posted Date  ICMJE August 30, 2017
Last Update Posted Date September 27, 2017
Study Start Date  ICMJE September 2011
Actual Primary Completion Date April 2015   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: July 28, 2017)
Mean Glomerular Filtration Rate (GFR) Calculated for Each Treatment Group Using the CKD-EPI Equation at Wk 52 [ Time Frame: Week 52 ]
GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI). A score of ≥ 90 means kidney function is normal. A score between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Scores between 30 and 59 indicates moderately reduced kidney function. Scores between 15 and 29 indicate severely reduced kidney function. Scores below 15 indicate very severe or endstage kidney failure.
Original Primary Outcome Measures  ICMJE
 (submitted: September 15, 2011)
Mean glomerular filtration rate calculated for each treatment group using the Chronic Kidney Disease Epidemiology Collaboration Equation (CKD-EPI) equation [ Time Frame: 52 weeks ]
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: July 28, 2017)
  • Count of Participants With Biopsy Proven Acute Rejection at Any Time Post-Transplant [ Time Frame: Transplantation through last study visit (up to week 156) ]
    Biopsy proven acute rejection was defined as histologic evidence of borderline or higher cellular rejection per local pathologist.
  • Count of Participants With Estimated Glomerular Filtration Rate (GFR) < 60 mL/Min/1.73 m^2 by CKD EPI [ Time Frame: Week 52, Week 104, and Week 156 ]
    GFR was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI). A score of ≥90 means kidney function is normal. A score between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Scores between 30 and 59 indicates moderately reduced kidney function. Scores between 15 and 29 indicate severely reduced kidney function. Scores below 15 indicate very severe or endstage kidney failure. This measure specifically looked at participants with scores less than 60.
  • Count of Participants by Chronic Kidney Disease (CKD) Stage Post-Transplant [ Time Frame: Week 52, Week 104, and Week 156 ]
    The stages of Chronic Kidney Disease are defined using the participant's GFR value as indicated below: Stage 1 if GFR value is ≥90; Stage 2 if GFR value is ≥60 and < 90; Stage 3A if 45 ≤GFR < 60; Stage 3B if 30 ≤ GFR < 45; Stage 4 if 15 ≤GFR < 30;l Stage 5 if GFR < 15. Stage 1 means kidney function is normal. Stage 2 indicates mildly reduced kidney function, pointing to kidney disease. Stages 3A and 3B indicate moderately reduced kidney function. Stage 4 indicates severely reduced kidney function. Stage 5 indicates very severe or end stage kidney failure.
  • Count of Participants With CKD Stage 4 or 5 [ Time Frame: Week 52, Week 104, and Week 156 ]
    The stages of Chronic Kidney Disease are defined using the participant's GFR value as indicated below. Stage 1 if GFR value is ≥90; Stage 2 if 60 ≤ GFR < 90; Stage 3A if 45 ≤ GFR < 60; Stage 3B if 30 ≤ GFR < 45; Stage 4 if 15 ≤ GFR < 30; Stage 5 if GFR < 15. Stage 1 means kidney function is normal. Stage 2 indicates mildly reduced kidney function, pointing to kidney disease. Stages 3A abd 3B indicate moderately reduced kidney function. Stage 4 indicates severely reduced kidney function. Stage 5 indicates very severe or end stage kidney failure.
  • Mean Calculated eGFR Using MDRD 4 Variable Model [ Time Frame: Week 52, Week 104, and Week 156 ]
    The estimated Glomerular Filtration Rate (eGFR) was calculated using the Modification of Diet in Renal Disease equation (MDRD). A score of ≥90 means kidney function is normal. A score between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Scores between 30 and 59 indicates moderately reduced kidney function. Scores between 15 and 29 indicate severely reduced kidney function. Scores below 15 indicate very severe or endstage kidney failure.
  • The Slope of eGFR by CKD-EPI Over Time Based on Serum Creatinine [ Time Frame: Week 52, Week 104, and Week 156 ]
    The estimated Glomerular Filtration Rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI). A score of ≥90 means kidney function is normal. A score between 60 and 89 indicates mildly reduced kidney function, pointing to kidney disease. Scores between 30 and 59 indicates moderately reduced kidney function. Scores between 15 and 29 indicate severely reduced kidney function. Scores below 15 indicate very severe or endstage kidney failure. An estimate of the slope, or change over time, in eGFR was produced using standard statistical linear modeling procedures. The estimate was then re-scaled so that it can be interpreted as a change in eGFR per month. Positive numbers indicate increasing kidney function. Larger numbers indicate greater change in kidney function.
  • Count of Participants With Delayed Graft Function Post-Transplant [ Time Frame: Any time within the first week post-transplant ]
    Delayed graft function is defined as dialysis in the first week on one or more occasions for any indication other than the treatment of acute hyperkalemia in the setting of otherwise acceptable renal function
  • An Increase of One or More Grades of CAN/IFTA When Comparing the Implantation and Subsequent Protocol Biopsies [ Time Frame: Week 52, Week 104, and Week 156 ]
    CAN/IFTA grades reflect the severity of interstitial fibrosis and tubular atrophy present in the tissue obtained during a kidney biopsy. Higher grades indicate greater severity in interstitial fibrosis and tubular atrophy present the kidney biopsy tissue. The aim of this measure was to compare central lab reviewed pre-implantation biopsies to post-transplant biopsies, as pre-specified per protocol; however, the central lab had an inadequate set of biopsies to proceed with evaluation.
  • Count of Participants With CAN/IFTA Grade I, II or III at Any Time Post-transplant [ Time Frame: Transplantation through last study visit (up to week 156) ]
    CAN/IFTA grades were determined per local pathology interpretations of biopsy tissue. These grades reflect the severity of interstitial fibrosis and tubular atrophy present in the tissue obtained during a kidney biopsy. Higher grades indicate greater severity in interstitial fibrosis and tubular atrophy present the kidney biopsy tissue.
  • Count of Participants With Acute Cellular Rejection Grade Equal to or Greater Than IA, by the Banff 2007 Criteria [ Time Frame: Transplantation through last study visit (up to week 156) ]
    Acute cellular rejection is when lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages that cause tissue damage. Acute cellular rejection for this endpoint is defined as a grade ≥ IA by Banff 2007 criteria.
  • Count of Participants by Severity of First Acute Cellular Rejection by Wk 52 [ Time Frame: Transplantation through Week 52 ]
    Acute cellular rejection is when lesions at the site of the graft characteristically are infiltrated with large numbers of lymphocytes and macrophages that cause tissue damage. Acute cellular rejection for this endpoint is defined as a grade ≥ IA by Banff 2007 criteria. Severity is graded as IA, IB, IIA, IIB, or III, with IA being the mildest form of cellular rejection and III being the most severe form of cellular rejection. Originally, this endpoint was worded as "The severity of first and highest acute cellular rejection within the first 52 weeks." But since the highest grade for each subject coincided with the first ACR episode for each subject, only a summary of severity of the first episode is presented here.
  • Count of Participants With Antibody Mediated Rejection [ Time Frame: Transplantation through last study visit (up to week 156) ]
    Antibody mediated rejection (AMR) is defined as diffusely positive staining for C4d, presence of circulating anti-donor antibodies and morphologic evidence of acute tissue injury.
  • Type of Treatment of Rejection [ Time Frame: Transplantation through last study visit (up to week 156) ]
    Upon having a biopsy performed, persons often receive treatment for rejection based on the results of the biopsy, which may or may not have shown signs of rejection. Details of biopsy findings and corresponding treatment are presented here for each instance of treatment for rejection. Acronyms and abbreviations are defined below. ACR=Acute Cellular Rejection ATG=Anti-thymocyte globulin therapy Chr. AMR=Chronic Antibody Mediated Rejection Gd.=Grade IFTA=Interstitial Fibrosis and Tubular Atrophy IVIG=Intravenous Immunoglobulin therapy. Only 'for cause' biopsies were performed post-transplant; thus, it is possible for a participant to be included in the analysis population and not have a biopsy for this outcome measure.
  • Count of Participants With de Novo Anti-donor HLA Antibodies at Wk 52 [ Time Frame: Week 52 ]
    The presence of antibodies reactive to Histocompatibility Antigen (HLA) molecules expressed on the renal allograft have been associated with both acute and chronic injury to the transplanted kidney. The development of de novo anti- donor HLA antibodies may mean a person is more likely to reject the graft.
  • Count of Participants With Either New Onset Diabetes After Transplant (NODAT) or Impaired Fasting Glucose (IFG) at Wk 52 Based on Criteria Specified by the ADA and WHO [ Time Frame: Week 52 ]
    New onset diabetes is the development of diabetes post-kidney transplant. It was identified by the clinical sites caring for each participant and reported directly in the clinical database. Impaired fasting glucose (IFG) is a determination made by referencing glucose measurements obtained from a standard chemistry panel. Any fasting glucose measure that is between 110 and 125 mg/dL is classified as IFG. Acronyms: American Diabetes Association (ADA); World Health Organization (WHO).
  • Count of Participants With Treated Diabetes Between Day 14 and Wk 52 [ Time Frame: Day 14 to Week 52 ]
    Treated diabetes is defined as the receipt of oral medication or insulin for >14 days between 14 days and 52 weeks post-transplant
  • HbA1c Measured at Days 28 & 84, and Weeks 24, 36, 52, 72, 104 and 156 [ Time Frame: Day 28, Day 84, Week 24, Week 36, Week 52, Week 72, Week 104, Week 156 ]
    Hemoglobin A1c (HbA1c) measures the average blood glucose levels over 8-12 weeks, thus acting as a useful long-term gauge of blood glucose control. A value below 6.0% reflects normal levels, 6.0% to 6.4% reflects prediabetes, and a value of ≥ 6.5% reflects diabetes.
  • Standardized Blood Pressure Measurement at Wk 52 [ Time Frame: Week 52 ]
    A blood pressure measurement consists of two numbers: the systolic and diastolic pressures. Systolic pressure measures the pressure in blood vessels when the heart beats. Diastolic pressure measures the pressure in blood vessels between beats of the heart. Systolic measures of <120 and diastolic measures of <80 are considered normal. Systolic measures of 120-139 and diastolic measures of 80-89 are considered at risk (or pre-hypertension). Systolic measures of ≥140 and diastolic measures of ≥90 are considered high.
  • Count of Participants With Use of Anti-hypertensive Medications at Wk 52 [ Time Frame: Week 52 ]
    Anti-hypertensive medications are a class of drugs that are used to treat hypertension. The medications seek to prevent the complications of high blood pressure, such as stoke and myocardial infarction.
  • Fasting Lipid Profile (Total Cholesterol, Non-HDL Cholesterol, LDL, HDL, and Triglyceride) at Baseline and Wks 24, 52, 104 and 156 [ Time Frame: Baseline, Week 24, Week 52, Week 104, Week 156 ]
    A fasting lipid profiles measures total cholesterol, LDL cholesterol, HDL cholesterol, and triglyceride levels. These measurements are used in assessing one's risk of cardiovascular disease. Target ranges for each of these measures are detailed below. Total cholesterol: 75-169 mg/dL if age ≤ 20; 100-199 mg/dL if age ≥ 21; high values indicate risk of cardiovascular disease LDL cholesterol: <70 mg/dL for people with documented cardiovascular disease or metabolic syndrome; <100 mg/dL for people considered high risk for cardiovascular disease; <130 mg/dL for people considered low risk for cardiovascular disease; high values indicate risk of cardiovascular disease HDL cholesterol: 40mg/dL and higher; high values indicate reduced risk of cardiovascular disease Non-HDL cholesterol: 30 mg/dL above the target value for LDL cholesterol; high values indicate risk of cardiovascular disease Triglycerides: <150 mg/dL; high values indicate risk of cardiovascular disease
  • Count of Participants With Use of Lipid Lowering Medications at Baseline and Wks 24, 52, 104 and 156 [ Time Frame: Baseline, Week 24, Week 52, Week 104, Week 156 ]
    Lipid lowering medications are used in the treatment of high levels of fats (lipids), such as cholesterol in blood
  • Total Daily Prescribed Pill Number at Days 28 and 84, and Wks 24, 36, 52, 72, 104 and 156 [ Time Frame: Day 28, Day 84, Week 24, Week 36, Week 52, Week 72, Week 104, Week 156 ]
    This is a measure of the total number of pills a participant was prescribed on a given day
  • Number of Events of Death or Graft Loss [ Time Frame: Transplantation through last study visit (up to week 156) ]
    This measure counts deaths and graft loss occurring at any point post transplantation. Graft loss is defined as need for dialysis for greater than 30 days duration, allograft nephrectomy, or retransplantation.
  • Count of Participants With Rejection [ Time Frame: Transplantation through last study visit (up to week 156) ]
    The number of participants who were treated by their local physician for any type of rejection including, but not limited to cellular rejection and antibody- mediated rejection of the transplanted kidney regardless of the presence of a biopsy.
  • Number of All Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: Enrollment through last study visit (up to week 156) ]
    Adverse events were collected systematically from enrollment through last study visit. Displayed below are counts of all adverse events per treatment group (including both serious and non-serious adverse events). Separately counts of all adverse events determined to be serious are displayed per treatment group. More detail about adverse events for this trial is displayed in the 'Adverse Event' section.
  • Count of Participants With Infections Requiring Hospitalization or Systemic Therapy Reported as Serious Adverse Events [ Time Frame: Transplantation through last study visit (up to week 156) ]
    Infections of certain types (i.e., excluding those identified in the protocol as occurring commonly in this study population) were required to be reported as a serious adverse event if they required either inpatient hospitalization of prolongation of a current hospitalization.
  • Count of Participants With BKV and CMV Viremia (Local Center Monitoring) Reported as Adverse Events [ Time Frame: Transplantation through last study visit (up to week 156) ]
    Viral infections following renal transplantation is significant source of recipient morbidity and mortality, and a significant cause of allograft dysfunction and loss. Specific viruses were monitored during this study using participant blood samples. Acronyms: BK Polyoma Virus (BKV); Cytomegalovirus (CMV).
  • Count of Participants With EBV Infection as Reported on the Case Report Form as Adverse Events [ Time Frame: Transplantation through last study visit (up to week 156) ]
    Viral infections following renal transplantation is a significant source of recipient morbidity and mortality, and a significant cause of allograft dysfunction and loss. Specific viruses were monitored during this study using participant blood samples. Acronym: Epstein-Barr virus (EBV)
  • Count of Participants With Fever > 39 Degrees Celsius and Blood Pressure < 90mm Hg Within 24 Hours of Onset of Transplant Procedure [ Time Frame: 24 hours after transplantation ]
    Temperature of >39 degrees Celsius would be an indication of fever most often in response to an infection or illness. Systolic blood pressure <90mm Hg would be an indication of low blood pressure.
Original Secondary Outcome Measures  ICMJE
 (submitted: September 15, 2011)
  • Histological evidence of rejection and graft dysfunction [ Time Frame: 24 weeks ]
    Incidence of clinically suspected and biopsy proven acute rejection as defined by histologic evidence of rejection and graft dysfunction
  • Measures of renal function and injury [ Time Frame: 52, 104, and 156 weeks ]
    Measures include eGFR < 60 mL/min/1.73 m2 by CKD-EPI; change in chronic kidney disease (CKD) stages from baseline; proportion of subjects with defined CKD stage 4 or 5; mean calculated eGFR; slope of eGFR by CKD-EPI over time based on serum creatinine; incidence of delayed graft function; increase of one or more grades of chronic allograft nephropathy (CAN)/interstitial fibrosis and tubular atrophy (IFTA) when comparing the implantation and subsequent protocol biopsies; incidence of CAN/IFTA grade I, II or III
  • Assessment of the incidence and severity of rejection and anti-donor reactivity [ Time Frame: 52, 104, and 156 weeks ]
    Acute cellular rejection; severity of first and highest grade of acute cellular rejection; antibody mediated rejection; type of treatment of rejection; prevalence of de novo anti-donor HLA antibodies
  • Measures of cardiovascular and metabolic parameters [ Time Frame: 2 - 156 weeks ]
    Include incidence of new onset diabetes after transplant or impaired fasting glucose; incidence of treated diabetes; HbA1c; standardized blood pressure measurement and use of anti-hypertensive medications; fasting lipid profile
  • Incidence of graft rejection [ Time Frame: 156 weeks ]
  • Incidence of death or graft loss [ Time Frame: 156 weeks ]
  • Incidence of infections [ Time Frame: 156 weeks ]
  • Immune reactivity and function assessed by research laboratory assays [ Time Frame: 156 weeks ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Optimization of NULOJIX® Usage As A Means of Avoiding CNI and Steroids in Renal Transplantation
Official Title  ICMJE Optimization of NULOJIX® (Belatacept) Usage as a Means of Avoiding CNI and Steroids in Renal Transplantation (CTOT-10)
Brief Summary The purpose of this study was to assess whether a new drug, Nulojix® (belatacept), would minimize serious long term side effects associated with anti-rejection medications while still protecting the new kidney from damage. The researchers also wanted to learn more about the safety of this treatment and long term health of the transplanted kidney.
Detailed Description Dialysis or kidney transplant are the two ways to treat kidney failure. Transplant recipients have to take anti-rejection medications to prevent their immune system (the body's natural defense system against illness) from rejecting their new kidney. Most patients who undergo a kidney transplant must take these anti-rejection medications for the rest of their lives. Taking standard anti-rejection medications for a long time can cause serious side effects, including kidney damage. There would be a benefit to finding new anti-rejection medications that work just as well, but don't damage the kidney.
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Kidney Transplantation
  • Renal Transplantation
Intervention  ICMJE
  • Drug: Alemtuzumab
    Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
    Other Name: Campath®
  • Drug: MMF

    All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.

    Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily.

    Other Names:
    • mycophenolate mofetil
    • CellCept®
  • Biological: Basiliximab
    Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication[s])
    Other Name: Simulect®
  • Drug: Short-term Tac
    Short-term (3 months)
    Other Names:
    • tacrolimus
    • Prograf®
  • Drug: tacrolimus
    maintenance
    Other Name: Prograf®
  • Biological: Belatacept
    maintenance
    Other Name: Nulojix®
  • Drug: methylprednisolone
    All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
    Other Name: MEDROL®
Study Arms  ICMJE
  • Active Comparator: Tac maintenance

    Group 1 Study Therapy Regimen:Induction with alemtuzumab and maintenance immunosuppression with tacrolimus and mycophenolate mofetil (MMF).

    Campath® (alemtuzumab); long-term Prograf® (tacrolimus), or equivalent ; CellCept® (mycophenolate mofetil- MMF), or equivalent , and 4 day course of MEDROL® (methylprednisolone)

    Interventions:
    • Drug: Alemtuzumab
    • Drug: MMF
    • Drug: tacrolimus
    • Drug: methylprednisolone
  • Experimental: Belatacept maintenance

    Group 2 Study Therapy Regimen: Induction with alemtuzumab and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).

    Campath® (alemtuzumab); Nulojix® (belatacept); CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL®(Methylprednisolone)

    Interventions:
    • Drug: Alemtuzumab
    • Drug: MMF
    • Biological: Belatacept
    • Drug: methylprednisolone
  • Experimental: Basiliximab induction/Short-term Tac

    Short term = 3 months

    Group 3 Study Therapy Regimen: Induction with 2 doses of basiliximab and tacrolimus for 84 days and maintenance with Nulojix® (belatacept) and mycophenolate mofetil (MMF).

    Simulect® (basiliximab); Nulojix® (belatacept); short-term course of Prograf® (tacrolimus), or equivalent; CellCept® (mycophenolate mofetil- MMF), or equivalent, and 4 day course of MEDROL® (methylprednisolone)

    Interventions:
    • Drug: MMF
    • Biological: Basiliximab
    • Drug: Short-term Tac
    • Biological: Belatacept
    • Drug: methylprednisolone
Publications * Newell KA, Mehta AK, Larsen CP, Stock PG, Farris AB, Mehta SG, Ikle D, Armstrong B, Morrison Y, Bridges N, Robien M, Mannon RB. Lessons Learned: Early Termination of a Randomized Trial of Calcineurin Inhibitor and Corticosteroid Avoidance Using Belatacept. Am J Transplant. 2017 Oct;17(10):2712-2719. doi: 10.1111/ajt.14377. Epub 2017 Jul 3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Terminated
Actual Enrollment  ICMJE
 (submitted: September 28, 2012)
19
Original Estimated Enrollment  ICMJE
 (submitted: September 15, 2011)
210
Actual Study Completion Date  ICMJE April 2015
Actual Primary Completion Date April 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Male or Female, 18-65 years of age at the time of enrollment;
  • Ability to understand and provide written informed consent;
  • Candidate for primary renal allograft from either a living or deceased-donor;
  • No known contraindications to study therapy using NULOJIX® (belatacept);
  • Female participants of childbearing potential must have a negative pregnancy test upon study entry;
  • Female and male participants with reproductive potential must agree to use FDA approved methods of birth control during participation in the study and for 4 months following completion of the study;
  • Flow-based PRA within last 12 months (in absence of a sensitizing event) of < 30% as determined by each participating study center. If the subject experienced a sensitizing event after the PRA test date, then the PRA must be repeated and confirmed <30%;
  • Negative crossmatch or a PRA of 0% on historic and admission sera as determined by each participating study center.
  • A documented negative TB test within the 12 months prior to transplant. If documentation is not present at the time of transplantation, and the subject does not have any risk factors for TB, a TB-specific interferon gamma release assay (IGRA) may be performed.

Exclusion Criteria:

  • Need for multi-organ transplant;
  • Recipient of previous organ transplant;
  • EBV sero-negative (or unknown) recipients;
  • Active infection including hepatitis B, hepatitis C, or HIV;
  • Individuals who have required treatment with prednisone or other immunosuppressive drugs within 1 year prior to transplant;
  • Individuals undergoing transplant using organs from extended criteria donor (ECD) or donation after cardiac death (DCD) donors;
  • HLA identical living donors;
  • Individuals at significant risk of early recurrence of the primary renal disease including FSGS and MPGN type 2 or any other disease that in the opinion of the investigator is at increased likelihood of recurrence and which may result in rapid decline in renal function;
  • Individuals previously treated with NULOJIX® (belatacept);
  • Any condition that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements;
  • Use of investigational drugs within 4 weeks of enrollment;
  • Known hypersensitivity to mycophenolate mofetil (MMF) or any of the drug's components;
  • Administration of live attenuated vaccine(s) within 8 weeks of enrollment.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01436305
Other Study ID Numbers  ICMJE DAIT CTOT-10
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party National Institute of Allergy and Infectious Diseases (NIAID)
Study Sponsor  ICMJE National Institute of Allergy and Infectious Diseases (NIAID)
Collaborators  ICMJE Clinical Trials in Organ Transplantation
Investigators  ICMJE
Study Chair: Kenneth Newell, MD, PhD Emory University
Principal Investigator: Christian P. Larsen, MD, DPhil Emory University
PRS Account National Institute of Allergy and Infectious Diseases (NIAID)
Verification Date August 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP